Search
Search Results
##search.searchResults.foundPlural##
-
ASSOCIATION OF BASELINE PLATELET COUNT WITH COMPLETE REMISSION, SEVERE BLEEDING, AND 24-MONTH OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE COHORT STUDY
53PDF: 34Suppl. Files: 7Html: 7Html Suppl. Files: 7 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2275PDF: 1834HTML: 836 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2928PDF: 1052HTML: 5639 -
-
REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE
12936PDF: 1730HTML: 4350Cover letter: 222Figure 1: 231 -
IMPACT OF QUALITATIVE AND QUANTITATIVE IMMUNOPARESIS ON EARLY INFECTION RISK IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA Immunoparesis and early infection risk in myeloma
197PDF: 667HTML: 63 -
The MINI-POLATUZUMAB VEDOTINE PLUS CHP (POLA-R-CHP) VS. MINI-R-CHOP IN PATIENTS OVER 80 YEARS OF AGE WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, PROPENSITY SCORE-MATCHED ANALYSIS STRATIFIED BY SIMPLIFIED FRAILTY SCORE PolaRCHP vs. RCHOP for older patients
1456PDF: 483HTML: 142 -
-
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2138PDF: 882HTML: 360 -
THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies
2181PDF: 599HTML: 365 -
THE PERFORMANCE OF HOMA 2 COMPARED TO DYNAMIC MARKERS OF INSULIN SECRETION AND SENSITIVITY/RESISTANCE FOR PREDICTING DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: THE EXPERIENCE OF A SINGLE CENTRE HOMA 2 and DYNAMIC MARKERS OF INSULIN SECRETION FOR PREDICTING DYSGLYCEMIA in TDT
195PDF: 182HTML: 48 -
PREVENTION OF ? THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS.
3176PDF: 1306HTML: 11860 -
CHILDREN IN CORONAVIRUSES’ WONDERLAND: WHAT CLINICIANS NEED TO KNOW Corona virus and Children
1526PDF: 1006HTML: 511 -
PATHOBIOLOGY OF HODGKIN LYMPHOMA
3347PDF: 1511HTML: 5966Fig1-Ag-Pil: 259Ag-Pil Fig.2: 259 -
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL
4552PDF: 3734HTML: 373 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1466HTML: 641PDF: 876 -
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1792PDF: 1319HTML: 613 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2555HTML: 303PDF: 940 -
IDENTİFİCATİON OF LEİSHMANİA TROPİCA FROM PEDİATRİC VİSCERAL LEİSHMANİASİS İN SOUTHERN MEDITERRANEAN REGION OF TURKEY. Molecular characterization of pediatric visceral leishmaniasis
1090PDF: 741HTML: 275 -
THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.
4155PDF: 1197HTML: 2106Fig.1: 228Fig. 2: 123Table 1: 224Table2: 243Table 3: 223 -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1807PDF: 1233HTML: 332 -
-
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2569PDF: 1734HTML: 518 -
FEASIBILITY AND OUTCOME OF FIRST-LINE AUTOTRANSPLANT-BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED > 65 YEARS: MONOCENTRIC RETROSPECTIVE REAL-WORLD ANALYSIS Outcomes of ASCT in NDMM elderly fit patients
1094PDF: 650Html: 172 -
Follicular Lymphoma: A Clinicopathological Analysis from a Tertiary care Institute in Southern India
3522PDF: 820HTML: 3022Figure 1a and 1b: 170Figure 2: 178Figure 3: 197Figure 4: 177Figure 5: 182Tables 1-5: 166







